These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9826368)

  • 1. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.
    Porgador A; Staats HF; Itoh Y; Kelsall BL
    Infect Immun; 1998 Dec; 66(12):5876-81. PubMed ID: 9826368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection.
    Wiley JA; Hogan RJ; Woodland DL; Harmsen AG
    J Immunol; 2001 Sep; 167(6):3293-9. PubMed ID: 11544317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization.
    Staats HF; Bradney CP; Gwinn WM; Jackson SS; Sempowski GD; Liao HX; Letvin NL; Haynes BF
    J Immunol; 2001 Nov; 167(9):5386-94. PubMed ID: 11673557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
    Simmons CP; Mastroeni P; Fowler R; Ghaem-maghami M; Lycke N; Pizza M; Rappuoli R; Dougan G
    J Immunol; 1999 Dec; 163(12):6502-10. PubMed ID: 10586042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
    Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
    Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of mucosal adjuvants on antigen passage and CD4+ T cell activation during the primary response to airborne allergen.
    Wikstrom ME; Batanero E; Smith M; Thomas JA; von Garnier C; Holt PG; Stumbles PA
    J Immunol; 2006 Jul; 177(2):913-24. PubMed ID: 16818746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naegleria fowleri immunization modifies lymphocytes and APC of nasal mucosa.
    Carrasco-Yepez MM; Campos-Rodríguez R; Reséndiz-Albor AA; Peña-Juárez C; Contis-Montes de Oca A; Arciniega-Martínez IM; Bonilla-Lemus P; Rojas-Hernandez S
    Parasite Immunol; 2018 Mar; 40(3):. PubMed ID: 29243267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the generation and maintenance of mucosal cytotoxic T lymphocytes against human immunodeficiency virus type 1 Gag in mice.
    Yoshizawa I; Mizuochi T; Ogata A; Murakami M; Yagita H; Takahashi Y; Mizuochi T; Takemori T; Tsunetsugu-Yokota Y
    AIDS Res Hum Retroviruses; 2003 Jun; 19(6):469-79. PubMed ID: 12882656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches.
    Heritage PL; Underdown BJ; Arsenault AL; Snider DP; McDermott MR
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1256-62. PubMed ID: 9351630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
    Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
    J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments.
    Velge-Roussel F; Marcelo P; Lepage AC; Buzoni-Gatel D; Bout DT
    Infect Immun; 2000 Feb; 68(2):969-72. PubMed ID: 10639474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A; Gilboa E
    J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue.
    Sabirov A; Metzger DW
    Vaccine; 2008 Mar; 26(12):1566-76. PubMed ID: 18281130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization.
    Wu HY; Nikolova EB; Beagley KW; Eldridge JH; Russell MW
    Infect Immun; 1997 Jan; 65(1):227-35. PubMed ID: 8975916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin.
    Luci C; Hervouet C; Rousseau D; Holmgren J; Czerkinsky C; Anjuère F
    J Immunol; 2006 Mar; 176(5):2749-57. PubMed ID: 16493030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
    Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
    J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens.
    Bowen JC; Nair SK; Reddy R; Rouse BT
    Immunology; 1994 Mar; 81(3):338-42. PubMed ID: 8206507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site.
    Wu HY; Nguyen HH; Russell MW
    Scand J Immunol; 1997 Nov; 46(5):506-13. PubMed ID: 9393634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.